full_name	preferred_name	is_ici_inhibitor	ici_pathway	is_aVEGF	is_aBRAF	is_aMAPK	is_chemo	name_aliases	description
Biochemo		F			F		T		
Trametinib		F			F	T	T		MEK inhibitor
Dabrafenib		F			T		F		MEK inhibitor; potent inhibitor of the RAF proteins BRAF and CRAF through ATP competitive binding of the active conformation of BRAF kinase
IL-2		F			F		F		Increases NKCs
Ribociclib		F			F		T		CDK inhibitor
Binimetinib		F			F	T	T		MEK 1 and MEK 2 protein inhibitor
CVD		F			F		T	Cisplatin, Dacarbazine, Vinblastine	
Interferon		F			F		F		Increases NKCs
Dacarbazine		F			F		T		DTIC methylates nucleic acids, causing DNA damage resulting in growth arrest and cell death
Temozolomide	TMZ	F			F		T	Temodar, Temo	methylates guanine
Dasatinib		F			F		T		kinase inhibitor
Temodar	TZM	F			F		T	Temozolomide, Temo	methylates guanine
TLR		F			F		F		toll-like receptor agonist
gp100 vaccine		F			F		F		targets melanocytes
Abraxane		F			F		T	paclitaxel	
Carboplatin		F			F		T		Platinum chemo
Doxycycline		F			F		F		inhibits protein synthesis in bacteria including mitochondria; Expression of stem cell factors Oct4, Sox2, Nanog and CD44 were also significantly downregulated after doxycycline treatment
Vemurafenib		F			T		F		blocks BRAF; used on patients with BRAF mutation V600E
IL-21+		F			F		F		Increases NKCs
Cisplatin		F			F		T		Platinum chemo
Velban		F			F		T		Inhibits microtuble assembly
Taxol		F			F		T		
Trientine		F			F		T	Triethylenetetramine, TETA	telomerase inhibiting
Gleevec		F			F		T		Tyrosine kinase inhibitor
Nivolumab	Nivo	T	PD1		F		F		immune checkpoint inhibitor
Ecorafenib		F			T		F		blocks BRAF; used on patients with BRAF mutation V600E
TIL		F			F		F		
MAGE		F			F		F		CTA that triggers body to attack MAGE overexpression in melanoma
Vinblastine		F			F		T		mitotic inhibitor
Trametibib		F			F		T		MEK inhibitor
Decarbazine		F			F		T		methylates guanine
AMG 337		F			F		F		inhibitor of the adenosine transporter; MET kinase imhibitor
TIC		F			F		F		tumor-initiating cells
BCNU		F			F		T		crosslinks DNA
Tamoxifen		F			F		F		blocks estrogen receptors
Paclitaxel		F			F		T	Abraxane	
DCVax		F			F		F		activated dendritic cells
ADI-PEG		F			F		T		Breaks down asparagine
GM-CSF		F			F		F		improves recovery of white blood cells following chemo
M-Vax		F			F		F		Irradiated cancer cells
Mel44		F			F		F		Melanoma peptides
PEG		F			F		T	Pegaspargase	Breaks down asparagine
IL-10		F			F		F		enhances vaccine-induced T cell responses
Ipilimumab	Ipi	T	CTLA4	F	F	F	F	Yervoy	Binds CTLA4, reducing its ability to upregulate cell division by binding C28
Pembrolizumab	Pembro	T	PD1	F	F	F	F	Keytruda	
MK3475	Pembro	T	PD1						
ADZ2014		F		F	F	F	F	Vistusertib	
CPT11		F		F	F	F	T	Camptosar, Irinotecan	
Docetaxal		F		F	F	F	T	Taxotere	
Vismodegib		F		F	F	F	F	Erivedge	
AZD6738		F		F	F	F	F		impact ATR pathway checkpoint for DDR ( DNA Damage Response ) establishment
FOLFIRI		F		F	F	F	T	Fonic Acid + Fluorouracil + Irinotecan	
FOLFOX		F		F	F	F	T	Folinic Acid + Fluorouacil + Oxiliplatin	
Ramucrimab		F		T	F	F	F		Binds VEGF2 antigen with high affnity preventing typical activation by VEGFR, thus downregulation of angiogeneis in tumor tissue
XELOX		F		F	F	F	T	Oxaliplatin and capecitabine	
Lapatinib		F		F	F	F	F	Tykerb and Tyverb	
DXP		F		F	F	F	T	docetaxel, cisplatin and capecitabine	
DP									
SOX		F		F	F	F	T	S-1 and oxaliplatin	
SP		F		F	F	F	T	S-1 plus cisplatin	
XP		F		F	F	F	T	Capecitabine and cisplatin	
Herceptin		F		F	F	F	F	Trastuzumab	
FGFR2									
Selumetinib		F		F	F	T	F	Koselugo	Inhibits MEP1
Volitinib		F		F	F	F	F		
FPA144-001		F		F	F	F	F	Bemarituzumab	
ADZ1775		F		F	F	F	F		used in combination with chemo typically as it makes cells more succepble to radiation and chemo
ADZ5363				F	F	F	F	capivasertib	
Cemiplimab		T	PD1						
Atezolizumab	Atezo	T	PD-L1						
Avelumab		T	PD-L1						
Durvalumab		T	PD-L1						
Sunitinib				T					
Bevacizumab	Bev			T					
Ironotecan							T		
Lomustine							T		